Cohesive Technologies Inc. announced today that it has entered into a collaborative agreement with Mayo Clinic to increase patient sample throughput and improve data quality using Cohesive's proprietary turbulent flow chromatography (TurboFlow? technology) systems for clinical assays using tandem mass spectrometry (MS/MS).
Cohesive Technologies Inc. announced today that it has entered into a collaborative agreement with Mayo Clinic to increase patient sample throughput and improve data quality using Cohesive's proprietary turbulent flow chromatography (TurboFlow technology) systems for clinical assays using tandem mass spectrometry (MS/MS).
The collaboration has been established to accelerate the development of clinical assays in such areas as endrocrinology, toxicology, drug monitoring, and neonatal screening. As part of the collaboration, the companies will share in the development of new TurboFlow and mass spectrometry methods in order to improve the quality and efficiency in diagnostics for adults, children, and newborns. These methods will be based on Mayo Clinic's goals for throughput and the potential impact to patients.
While tandem mass spectrometry is being widely adopted in clinical diagnostics to drive down false positives and improve limits of detection, these labs struggle with the lengthy sample preparation required and high capital costs associated with tandem mass spectrometry. Cohesive's systems have been adopted because they address these sample preparation bottlenecks and also reduce capital requirements, thus making MS/MS more economically feasible for the diagnostic marketplace.
"The progress we have made applying turbulent flow chromatography and multiplexing to the clinical diagnostic marketplace, along with Mayo's clinical expertise, make this program ideal for extending the reach of LC-MS/MS," said Peter Glick, President and CEO. "We see this collaboration as a way to develop more powerful methods sooner, which will enable physicians and their patients to get more accurate results, and thus improve the quality of care."
Cohesive Technologies develops, manufactures, and markets novel liquid chromatography systems and chemistries for the pharmaceutical, biotechnology, and clinical diagnostic marketplace. These products have made Cohesive a leader in creating new tools for high-throughput bioanalysis. Detailed information about Cohesive Technologies' products and technology can be found on its website, http://www.cohesivetech.com, which also has a bibliography of publications by Cohesive customers describing their successful use of the technology.
Accelerating Monoclonal Antibody Quality Control: The Role of LC–MS in Upstream Bioprocessing
This study highlights the promising potential of LC–MS as a powerful tool for mAb quality control within the context of upstream processing.
Using GC-MS to Measure Improvement Efforts to TNT-Contaminated Soil
April 29th 2025Researchers developing a plant microbial consortium that can repair in-situ high concentration TNT (1434 mg/kg) contaminated soil, as well as overcome the limitations of previous studies that only focused on simulated pollution, used untargeted metabolone gas chromatography-mass spectrometry (GC-MS) to measure their success.
Prioritizing Non-Target Screening in LC–HRMS Environmental Sample Analysis
April 28th 2025When analyzing samples using liquid chromatography–high-resolution mass spectrometry, there are various ways the processes can be improved. Researchers created new methods for prioritizing these strategies.
Potential Obstacles in Chromatographic Analyses Distinguishing Marijuana from Hemp
April 28th 2025LCGC International's April series for National Cannabis Awareness Month concludes with a discussion with Walter B. Wilson from the National Institute of Standard and Technology’s (NIST’s) Chemical Sciences Division regarding recent research his team conducted investigating chromatographic interferences that can potentially inflate the levels of Δ9-THC in Cannabis sativa plant samples, and possible solutions to avoid this problem.